Talphera, Inc. TLPH

TLPH Company Overview

Talphera, Inc. (Nasdaq: TLPH) is a biotechnology and specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings, particularly acute care and procedural environments. The company operates within the biopharmaceutical and hospital-based therapeutics industries, with a strategic emphasis on pain management, critical care, and non-opioid therapeutic approaches. Talphera is the successor to AcelRx Pharmaceuticals, Inc., which rebranded following a broader strategic repositioning centered on expanding beyond its historical acute pain portfolio.

The company’s primary business activities have included the development of sublingual and injectable therapeutics intended for hospital and outpatient procedural settings. Talphera has historically derived value from proprietary drug-delivery technologies and clinical-stage pharmaceutical assets. Its strategic positioning has centered on addressing unmet needs in controlled medical environments where rapid onset, ease of administration, and reduced operational complexity are important. Public filings and company materials indicate that the company has increasingly focused on late-stage and specialty-care assets following restructuring efforts and portfolio prioritization initiatives.